Inteleukin-23 inhibitors have made a name for themselves in the treatment of psoriasis...
- EULAR 2018: key pipeline developments in psoriatic arthritis
- Lanabecestat termination: another blow for BACE inhibitors
- EULAR 2018: Focus on infliximab biosimilars in rheumatoid arthritis
- Northwest Bio’s DCVax-L: is the hype warranted for glioblastoma patients?
- ASCO data sees Merck’s Keytruda pull ahead of Roche’s Tecentriq in lung cancer
New administration forms for pharmaceutical agents becoming increasingly important
The packaging industry has the responsibility to follow this trend and to develop new designs and present solutions. The idea behind COMEDCO is to make it easy and safe for pharmaceutical companies to start their new developments in transdermal and ODF products.
Novartis finds Jakavi can help real-world blood cancer patients
Novartis has reported positive data from a real-world comparison study of its Jakavi (ruxolitinib) drug conducted to treat patients with polycythemia vera (PV), a rare incurable blood cancer.
EULAR 2018: key pipeline developments in psoriatic arthritis
Inteleukin-23 inhibitors have made a name for themselves in the treatment of psoriasis following the launch of J&J’s Tremfya in July 2017 and Sun Pharmaceutical’s Ilumya in March 2018.
Lanabecestat termination: another blow for BACE inhibitors
After the disappointing failures of highly anticipated anti-amyloid pipeline drugs, such as Pfizer/Johnson & Johnson’s bapineuzumab and Eli Lilly’s solanezumab, the focus of research in Alzheimer’s has increasingly turned to beta-secretase (BACE) inhibitors. Unlike the injectable monoclonal antibodies, the BACE inhibitors are oral small molecules.
EULAR 2018: Focus on infliximab biosimilars in rheumatoid arthritis
On June 14th, Biocad presented Week 14 results on the safety and efficacy of BCD-055 (infliximab biosimilar) from the ongoing Phase III LIRA clinical trial. The international, multicenter, double-blind, placebo-controlled trial randomised (2:1) 426 adult patients with active rheumatoid arthritis (RA) to receive BCD-055 or infliximab innovator for 54 weeks both at a dose of 3mg/kg. At Week 14, 71.6% of patients receiving BCD-055 compared with 67.9% of patients receiving Remicade achieved American College of Rheumatology 20% improvement criteria (ACR20) (p=0.587).
The ten most promising cancer drugs being trialled
To meet rising demand, companies worldwide are striving to develop cost-effective and innovative therapies for a wide variety of cancer types. Pharmaceutical-technology.com lists some of the most promising oncology drugs that are currently undergoing late-stage clinical trials.
Northwest Bio’s DCVax-L: is the hype warranted for glioblastoma patients?
Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer; little progress has been made toward its treatment in the past decade. However, on May 29 Northwest Bio revealed Phase III interim data for its personalised autologous dendritic cell vaccine, DCVax-L, outlining highly encouraging survival data for newly diagnosed glioblastoma patients.
ASCO data sees Merck’s Keytruda pull ahead of Roche’s Tecentriq in lung cancer
Roche’s Tecentriq may have fallen behind Merck’s Keytruda in the first-line non-small cell lung cancer population following releases at the annual meeting of the American Society of Clinical Oncology.
Single-country studies dominate immuno-oncology trials, 2008-2017
GlobalData has reviewed the location of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017.
Eli Lilly’s Olumiant: how will it far among JAK inhibitors?
On June 1, Eli Lilly’s Olumiant (baricitinib) 2mg tablets received FDA approval for adult patients with moderately to severely active rheumatoid arthritis (RA) following a complete response letter from the FDA the previous year.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.